Mostra i principali dati dell'item

dc.creatorKarapetsa M., Tsolaki V., Arabatzis M., Petinaki E., Velegraki A., Zakynthinos E.en
dc.date.accessioned2023-01-31T08:31:27Z
dc.date.available2023-01-31T08:31:27Z
dc.date.issued2019
dc.identifier10.1016/j.jiph.2018.12.015
dc.identifier.issn18760341
dc.identifier.urihttp://hdl.handle.net/11615/74425
dc.description.abstractSepsis related to Candida famata (C. famata) fungemia is extremely rare in immunocompetent patients. Moreover, septic shock has not been reported due to this yeast. A previously healthy young multi-trauma male, presented septic shock from C. famata, after he had been admitted in the Intensive Care Unit (ICU) due to haemorrhagic shock. Risk factors for candidemia in ICU patients are the presence of a central venous catheter (CVC), Total Parenteral Nutrition (TPN), use of broad-spectrum antimicrobials, immunosuppression and the length of ICU stay. The presence of CVCs, prior use of antibiotics, prolonged hospitalization, disruption of skin flora and immunocompromised states have been identified as predisposing risk factors for C. famata fungemia. It is worth noting that the present case concerns a non-immunocompromised patient, but long ICU stay and brain injury may indicate a state of immunoparalysis. Identification of the yeast was performed by partial amplification and sequencing of the 26S ribosomal DNA gene [hypervariable region D1/D2; partial sequencing of the act1 gene confirmed the identity of the strain as Debaryomyces hansenii (GenBank submission ID: 1688297)] The patient quickly recovered from sepsis after initiation of amphotericin B and was discharged on the 60th day. © 2019 The Authorsen
dc.language.isoenen
dc.sourceJournal of Infection and Public Healthen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85059569356&doi=10.1016%2fj.jiph.2018.12.015&partnerID=40&md5=9bc13164ac2240a1d6004fa0e8409d26
dc.subjectamphotericin Ben
dc.subjectanidulafunginen
dc.subjectantiinfective agenten
dc.subjectcolistinen
dc.subjectdaptomycinen
dc.subjectDNA 26Sen
dc.subjectmetronidazoleen
dc.subjecttigecyclineen
dc.subjectamphotericin Ben
dc.subjectantifungal agenten
dc.subjectadulten
dc.subjectadult respiratory distress syndromeen
dc.subjectArticleen
dc.subjectartificial embolizationen
dc.subjectcandidemiaen
dc.subjectcase reporten
dc.subjectclinical articleen
dc.subjectDebaryomyces hanseniien
dc.subjectdebridementen
dc.subjecterythrocyteen
dc.subjectfracture external fixationen
dc.subjectfungemiaen
dc.subjecthematothoraxen
dc.subjecthemorrhagic shocken
dc.subjecthospitalizationen
dc.subjecthumanen
dc.subjecthuman cellen
dc.subjectimmunosuppressive treatmenten
dc.subjectintensive care uniten
dc.subjectinternal iliac arteryen
dc.subjectlength of stayen
dc.subjectloading drug doseen
dc.subjectlung contusionen
dc.subjectmaleen
dc.subjectpriority journalen
dc.subjectrisk factoren
dc.subjectseptic shocken
dc.subjectsplenectomyen
dc.subjectsurgical infectionen
dc.subjecttotal parenteral nutritionen
dc.subjecttraumatic brain injuryen
dc.subjecturinary tract infectionen
dc.subjectcandidemiaen
dc.subjectcomplicationen
dc.subjectDebaryomycesen
dc.subjectgeneticsen
dc.subjectimmunocompetenceen
dc.subjectinjuryen
dc.subjectintensive careen
dc.subjectintensive care uniten
dc.subjectmicrobiologyen
dc.subjectseptic shocken
dc.subjecttreatment outcomeen
dc.subjectAdulten
dc.subjectAmphotericin Ben
dc.subjectAntifungal Agentsen
dc.subjectCandidemiaen
dc.subjectCritical Careen
dc.subjectDebaromycesen
dc.subjectHumansen
dc.subjectImmunocompetenceen
dc.subjectIntensive Care Unitsen
dc.subjectMaleen
dc.subjectRisk Factorsen
dc.subjectShock, Septicen
dc.subjectTreatment Outcomeen
dc.subjectWounds and Injuriesen
dc.subjectElsevier Ltden
dc.titleSeptic shock due to Candida famata (Debaryomyces hansenii) candidemia in an ICU immunocompetent trauma-patienten
dc.typejournalArticleen


Files in questo item

FilesDimensioneFormatoMostra

Nessun files in questo item.

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item